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Abstract
The HIV/AIDS pandemic is primarily caused by HIV-1. Another virus type, HIV-2, is found mainly in West African
countries. We hypothesized that population migration and mobility in Africa may have facilitated the introduction
and spreading of HIV-2 in Mozambique. The presence of HIV-2 has important implications for diagnosis and choice
of treatment of HIV infection. Hence, the aim of this study was to estimate the prevalence of HIV-2 infection and
its genotype in Maputo, Mozambique.
HIV-infected individuals (N = 1,200) were consecutively enrolled and screened for IgG antibodies against HIV-1
gp41 and HIV-2 gp36 using peptide-based enzyme immunoassays (pepEIA). Specimens showing reactivity on the
HIV-2 pepEIA were further tested using the INNO-LIA immunoblot assay and HIV-2 PCR targeting RT and PR genes.
Subtype analysis of HIV-2 was based on the protease gene.
After screening with HIV-2 pepEIA 1,168 were non-reactive and 32 were reactive to HIV-2 gp36 peptide. Of this
total, 30 specimens were simultaneously reactive to gp41 and gp36 pepEIA while two samples reacted solely to
gp36 peptide. Only three specimens containing antibodies against gp36 and gp105 on the INNO-LIA immunoblot
assay were found to be positive by PCR to HIV-2 subtype A.
The proportion of HIV-2 in Maputo City was 0.25% (90%CI 0.01-0.49). The HIV epidemic in Southern Mozambique is
driven by HIV-1, with HIV-2 also circulating at a marginal rate. Surveillance program need to improve HIV-2
diagnosis and consider periodical survey aiming to monitor HIV-2 prevalence in the country.
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Introduction
Human immunodeficiency virus (HIV) type 2 (HIV-2) is
a related but distinct virus from HIV-1, in spite of hav-
ing similar gene products, genetic organization and cell
tropism in vitro. HIV-2 also shows decreased cell killing,
syncytium formation, and replication rates when com-
pared with HIV-1. These features may justify the lower
transmissibility of HIV-2, as well as its reduced patho-
genicity and longer clinical course. Nevertheless, HIV-2
can cause immunosuppression and progression to AIDS
[1-3]. HIV-2 was first isolated in West Africa in 1986
and has been reported in many countries of Western
Africa such as the Gambia, Guinea, Ghana, Cape Verde,
Guinea-Bissau, Cote d’Ivoire, Liberia, Senegal, and Niger
[4,5]. Outside Africa, HIV-2 infection is sporadically
detected in countries with socioeconomic relations with
West Africa such as Portugal, Spain, France, United
Kingdom and India [6-9]. The presence of HIV-2 is not
regularly surveyed and generally assumed to be low in
other African countries outside West Africa. However,
in the last three decades there has been an increase in
population migration within Africa, mainly attributed to
regional wars, political upraises and even to increased
international travel inside Africa [3,10].
The laboratory diagnosis of HIV-2 infection is chal-
lenged by the high cross-reactivity rate between the two
viruses. Overall, HIV diagnosis is performed by a combi-
nation of one screening assay, often an Enzyme
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tern blot assay. However, the use of HIV-1 Western
blots may lead to misclassification of HIV-2- infected
individuals since HIV-1 and HIV-2 Western blots lack
specificity for type-specific diagnosis because there is
significant cross-reactivity to gag, pol, and env oligo-
meric proteins. PCR has been used as gold standard for
HIV-2 diagnosis but it still remains a research tool and
a commercial assay is not yet available [3,11,12].
The diagnosis of HIV-2 has important implications for
the choice of antiretroviral treatment (ART) regimens,
as HIV-2 strains are naturally resistant to non-nucleo-
side reverse transcriptase and fusion inhibitors and are,
at least in vitro, less sensitive to some protease inhibi-
tors [13]. Consequently, accurate diagnosis of HIV-2
infection is critical for clinical management of patients
[14,15].
Mozambique is situated in southeastern Africa and is
bordered by six countries: Tanzania, Malawi, Zambia,
Zimbabwe, Swaziland and South Africa and gained inde-
pendence from Portugal in 1975, after nearly five centu-
ries of Portuguese occupation. Furthermore, in the last
two decades, there have been a considerable number of
people from West Africa, Europe, and Asia visiting and
living in Mozambique. These migratory movements may
have facilitated the introduction and spreading of HIV-2
in Mozambique. Despite the existence of sporadic
reports, the prevalence of HIV-2 in Mozambique is lar-
gely unknown [16]. In this work, we utilized a combina-
tion of serological and molecular techniques to estimate
the prevalence of HIV-2 infection in Maputo City,
Mozambique.
Materials and methods
Study design and subjects
This was a cross-sectional study that enrolled indivi-
duals with a recent HIV diagnosis attending the Centro
de Saúde do Alto Maé outpatient clinic in Maputo City,
Mozambique. A total of 1,200 consecutive individuals
were recruited to participate at the time of routine CD4
+ T-lymphocyte (CD4+) count. After written informed
consent, two EDTA tubes were collected from each
volunteer for CD4+ count and HIV-2 screening test,
both performed at the Instituto Nacional de Saúde
(INS), Mozambique. Confirmatory serological testing
and HIV-2 molecular characterization was conducted at
the Federal University of Rio de Janeiro, Brazil. The
study protocol was approved in 2009 by the Mozambi-
can National Health Bioethics Committee under Proto-
col number 129/CNBS.
HIV serological assays
All individuals enrolled in this study had been pre-
viously diagnosed as HIV infected according to the
Mozambican algorithm for HIV diagnosis which
employs two sequential HIV-1/2 rapid tests: the Deter-
mine HIV 1/2 test (Abbott Laboratories, Tokyo, Japan),
used for screening and UniGold HIV test (Trinity Bio-
tech, Ireland), used to confirm initial reactivity on the
Determine assay. HIV infection is ascertained only if
both assays are reactive. Of note, both assays have the
HIV-2 gp36 antigen on the solid phase, and are able to
detect HIV-2 specific antibodies.
In addition to the HIV-1/HIV-2 specific peptide-EIA
(pepEIA) assay described below, two confirmatory sero-
logical assays were used in this study: INNO-LIA HIV I/
II Score (Innogenetics, Gent, Belgium) and Bio-Rad New
Lav Blot II (Bio-Rad, Marnes-la-Conquette, France).
In order to initially differentiate the reactivity against
HIV-1 and HIV-2 we used the same assay described by
Qiu et all [17]. Briefly, synthetic peptides, carrying 14
amino acid residues from the immunodominant regions
of transmembrane proteinso fH I V - 1( g p 4 1 )o rH I V - 2
(gp36) were synthesized with the addition of 7 non-spe-
cific residues at the amino-terminus (RGDKDGG) to
increase the solubility of both peptides. HIV-1 or HIV-2
peptides were coated onto wells on separate microplates
(Nalge Nunc International, Rochester, NY) at 5 μg/mL
in 100 μL of 10mM phosphate buffer saline (PBS), pH
7.4 for 2 hr at 37°C. Following five washes with PBS,
wells were blocked with 100 μL of BSA buffer (PBS with
0.05% Tween-20 and 0.5%BSA). Serum or plasma sam-
ples (diluted 1:100 in BSA buffer) were added to the
coated wells and incubated for 1 hr at 37°C. After the
wash, bound antibodies were detected by goat anti-
human IgG peroxidase conjugate (30 min at 37°C,
diluted in BSA buffer), followed by substrate (TMB)
incubation for 25 min at room temperature.
The cutoff values were arbitrarily set at 0.5 OD for
both EIAs; all negative specimens were below the cutoff
value. The criteria for interpreting results were as fol-
lows: 1) HIV-1 OD ≥ 0 . 5a n dH I V - 2O D<0 . 5w e r e
considered HIV-1 reactive only; (2) HIV-2 OD ≥ 0.5
and HIV-1 OD < 0.5 were considered HIV-2 reactive
only; 3) HIV-1 OD and HIV-2 OD ≥ 0.5 were consid-
ered HIV-1 and HIV-2 dually reactive and; 4) HIV-1
OD and HIV-2 OD < 0.5 were considered non reactive.
Samples dually reactive were further diluted 1:10 (to a
final serum dilution of 1:1,000) and retested on the
pepEIA, and the results were interpreted as above.
Molecular detection and characterization
Buffy coats from samples suspected of having HIV-2
were used for DNA extraction using a blood DNA
extraction kit (QIAamp, Qiagen, Hilden, Germany),
according to the manufacturer’s instructions. Detection
of HIV-2 proviral DNA was carried out using nested
polymerase chain reaction (PCR) of region pol (protease
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the protocol described by Colson et al [14]. Nested PCR
was performed using 5 μL of extracted genomic
DNAThe PCR conditions were 2,5U of Taq Platinum
DNA polymerase (Invitrogen Life Technologies, Carls-
bad, Calif), 1× polymerase buffer, 0.4 mM of each deox-
ynucleoside triphosphate, 3mM of Mgcl2,a n d2 5p m o l
of the outer primers (forward: H2Mp1, 5’-GGGAAA-
GAAGCCCCGCAACTTC-3’;reverse: H2Mp2, 5’-
GGGATCCATGTCACTTGCCA-3’)i nt h ef i r s tr o u n d .
This amplification was carried out in a 50 μl reaction
mixture to obtain a genomic fragment of 1,753 bp. The
cycling conditions were 94°C for 2 min, followed by 40
cycles of 94°C for 30sec, 56°C for 45 sec, and at 72°C
for 2 min) with one final cycle of 72°C for 7 min. The
2nd round was performed using 5 μL of the previous
amplification product and 25 pmol of the inner primers
(forward: H2Mp3, 5’-ACTTACTGCACCTCGAGCA-3’;
reverse: H2Mp4, 5’-CCCAAATGACTAGTGCTTCTT-
3’). Five microliters of the amplicon of the first-round
were added in the second-round of PCR and performed
under the same conditions of the 1st PCR to obtain a
genomic fragment of 1,507 bp. Amplicons were detected
by electrophoresis on 1,5% agarose gel and visualized
under UV light after ethidium bromide staining.
To detect HIV-1 nested PCR was designed to amplify
a 1000-bp fragment encompassing 297 bp of the pro-
tease gene and 703 bp of the RT gene. The conditions
were 2.5 mM MgCl2, 0.4 mM of each deoxynucleotide
triphosphate, 25 pmol of each primer (forward: K1F,
5’-5’ CAGAGCCAACAGCCCCACCA -3’; reverse: K2R,
5’- TTTTCCCACTAACTTCTGTCATTGAC-3’), and
1.25U of Taq Platinum DNA polymerase (Invitrogen,
CA, USA), 1x polymerase buffer and 5 μLo fD N A
genomic extracted in a final volume of 50 μL. The
thermal conditions of amplification in the thermocy-
cler device (ABI 9700, Applied Biosystems, USA) were:
94°C for 3 min, 5 cycles of denaturation at 94°C for 1
min, annealing at 55°C for 45 sec. and extension at 72°
C for 2 min followed by 30 cycles of denaturation at
94°C for 1 min, annealing at 57°C for 45 sec. and
extension at 72°C for 2 min. and incubation at 72°C
for 7 min. The secondround was done with 3 μLo f
the amplicon of the first-round and 25 pmol of inner
primers (forward: DP10, 5’-5 ’CAACTCCCTCTCA-
GAAGCAGGAGCCG 3’;r e v e r s e :R T 1 25 ’-A T C A G -
GATGGAGTTCATAACCCATCCA-3’)i nt h es a m e
conditions of the first-round. Amplicons of 1000bp
were detected by electrophoresis on 1% agarose gel
and visualized under UV light after ethidium bromide
staining [17-19].
For each run, HIV-1 and HIV-2 positive samples, in
addition to a genomic DNA from an individual serone-
gative for HIV-1/2, were used as controls. The gp41
immunodominant region (IDR) was sequenced following
the protocol previously described [20].
For sequencing analysis, PCR products corresponding
to 1000 bp and 1507 bp of HIV-1 and HIV-2 pol region
respectively were purified using QIAamp PCR purifica-
tion kit (Qiagen) according to the manufacturer’s
instructions. The amplicons were directly sequenced
using the BigDye Terminator v3.1 Cycle Sequencing Kit,
with a 3730 Automated DNA Sequencer (Applied Bio-
systems, USA).
Sequences were edited and aligned using BioEdit pro-
gram v5.0.9. (Department of Microbiology, North Caro-
lina State University, USA), and Clustal W algorithm,
respectively. Neighbor-joining (NJ) tree was built on
Mega 4.0 software. The NJ tree was evaluated by boot-
strap analysis of 1,000 replicates. The mean genetic dis-
tance between the Mozambican HIV-2 samples was
determined using substitution model on Mega 4.0
software.
Statistical analysis
Confidence Interval (CI) was used to address precision
of the proportion estimates and the degree of confi-
dence was set to 90% [21].
Results
We initially screened 1,200 specimens by parallel testing
with HIV-1 and HIV-2 pepEIA (Figure 1). One sample
(FEH0045) was non-reactive to the gp41 and gp36
derived peptide. Further testing with the Vironostika
HIV Uni-Form II plus O and the HIV-1 Western blot
was also negative. Consistently with this serological find-
ing, a PCR reaction set to amplify the reverse trasncrip-
tase and protease regions from HIV-1 and HIV-2 was
negative.. This sample was removed from analysis.
A total of 1,167 specimens were reactive only on the
HIV-1 gp41 pepEIA after the initial screening. Thirty
samples were simultaneously reactive to gp41 and gp36
peptides and after re-testing these specimens with a 1:10
dilution, 17 became reactive to HIV-1 peptide only. The
remaining 13 samples remained reactive to both HIV-1
and HIV-2 peptides (Table 1). Finally, two samples were
reactive with the gp36 peptide only after the initial
pepEIA 
N=1,200 
HIV-1 NRx 
HIV-2 NRx 
(N = 1)
HIV-1 NRx 
HIV-2 Rx 
(N = 2)
HIV-1 Rx 
HIV-2 Rx  
(N = 30)
HIV-1 Rx 
HIV-2 NRx 
(N = 1,167)
Figure 1 Results of the pepEIA screening test for HIV types 1
and 2 in 1,200 HIV infected patients followed-up at the Alto
Maé outpatient clinic. Rx = pepEIA reactive and NRx = pepEIA
non-reactive.
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persisted after 1:10 specimen dilution.
The 30 initially dually reactive samples and the two
HIV-2 reactive samples were further tested on the
INNO-LIA immunoblot assay (Table 1). All 30 pepEIA
dually reactive samples reacted against all five HIV-1
specific proteins present on the INNO-LIA (gp120,
gp41, p31, p24 and p17), except for sample FEH1196
that was negative for p17. The analysis of reactivity
against HIV-2 proteins (gp105 and gp36) revealed that
among the 17 samples that became HIV-2 negative after
re-testing with 1:10 sample dilution in the pepEIA assay,
Table 1 Serological and genomic tests results of 32 patients reactive on the pepEIA HIV-2 screening assay
Result of pepEIA screening
a Result of confirmatory assay Result of nested
PCR (Subtyping)
INNO-LIA HIV 1/2
b
Patient
code
HIV-1 HIV-2 HIV type
HIV-1 OD HIV-2 OD HIV-2 OD (1/10)
d p24 gp41 gp120 gp36 gp105 New
LAV Blot
c II (HIV-2)
HIV-1 HIV-2
FEH0251 2578 563 155 3 3 3 neg neg 1 nd POS (C) Neg
FEH0049 2886 592 356 3 3 3 neg neg 1 nd POS (C) Neg
FEH0220 2815 624 196 3 3 3 neg neg 1 nd POS (C) Neg
FEH0105 2820 694 283 3 3 3 neg neg 1 nd POS (C) Neg
FEH0345 2804 713 230 3 3 3 neg neg 1 nd POS (C) Neg
FEH0047 3024 718 310 3 3 3 2 neg 1-2 nd POS (C) Neg
FEH0190 2972 937 144 3 3 3 1 neg 1-2 nd POS (C) Neg
FEH0027 2979 947 273 2 3 3 neg neg 1 nd POS (C) Neg
FEH0596 2892 962 160 3 3 3 neg 1 1-2 Indeterm POS (C) Neg
FEH0281 2539 1086 296 3 3 3 2 neg 1-2 POS POS (C) Neg
FEH0226 3008 1275 416 3 3 2 2 neg 1-2 POS POS (C) Neg
FEH0210 2820 1619 393 3 3 3 1 neg 1-2 POS POS (C) Neg
FEH0244 2805 1695 291 2 3 +/- 2 neg 1-2 Indeterm POS (C) Neg
FEH1044 2645 1764 446 3 3 3 neg neg 1 nd POS (C) Neg
FEH0327 2885 2156 389 3 3 2 neg neg 1 nd POS (C) Neg
FEH0700 2405 699 116 +/- 4 2 neg 2 1-2 nd POS (C) Neg
FEH0687 2799 1485 279 1 4 3 neg neg 1 nd POS (C) Neg
FEH0086 2959 1426 755 3 3 3 neg neg 1 nd POS (C) Neg
FEH0394 2794 1794 864 3 3 3 1 neg 1-2 POS POS (C) Neg
FEH1049 3010 2146 729 3 3 3 neg neg 1 nd POS (C) Neg
FEH0875 2859 2222 702 2 3 3 neg neg 1 nd POS (C) Neg
FEH0982 2412 2261 1425 3 3 3 neg neg 1 nd POS (C) Neg
FEH0404 3031 2262 1054 3 3 3 neg neg 1 POS POS (C) Neg
FEH0857 2837 2272 1481 3 3 2 neg neg 1 nd POS (C) Neg
FEH0646 3008 2364 573 3 3 3 neg neg 1 POS POS (C) Neg
FEH1196 3017 2620 1145 2 3 3 neg neg 1 Indeterm POS (C) Neg
FEH1097 2996 2662 547 3 3 3 neg neg 1 nd POS (C) Neg
FEH1040 2996 2697 672 3 3 3 neg neg 1 nd POS (C) Neg
FEH0681 2882 2069 2988 2 4 3 1 neg 1-2 nd POS (C) Neg
FEH0089 2858 2809 1600 3 3 3 3 3 1-2 POS POS (C) POS (A)
FEH0726 197 2051 922 neg neg neg 3 1 2 POS Neg POS (A)
FEH0924 194 2779 2080 +/- neg neg 2 3 2 POS Neg POS (A)
aUnderlined numbers denotes reactivity on the pepEIA;
bOnly reactivity to antigens of interest is reported;
c nd, not tested; indeterm, indeterminate;
d assay performed with sample further diluted 1/10
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present on two samples and both bands were absent for
nine samples. Of the 13 samples that remained HIV-2
positive after pepEIA re-testing with 1:10 sample dilu-
tion, 10 did not react to gp36 or gp105 while two
reacted against gp36 only. Solely one sample (FEH0089)
reacted to both gp36 and gp105 HIV-2 proteins. The
two samples reactive on gp36 pepEIA only, reacted to
both HIV-2 gp36 and gp105 proteins. One of these spe-
cimens (FEH0726) did not react to any HIV-1 proteins
present on the INNO-LIA assay while the other
(FEH0924) showed weak reactivity to the HIV-1 p24
protein (Table 1).
In order to explore the discriminatory power of HIV-2
Western blot we have analyzed the capacity of 9 HIV-1/
HIV-2 dually reactive samples in recognizing HIV-2
proteins (Figure 2). The data indicated no discriminatory
pattern and, on the basis of the manufacturer’sW B
interpretation criteria, all samples could be considered
as HIV-2 positive. Likewise, the reactive on the HIV-1
Western blot from the 2 solely HIV-2 pepEIA reactive
samples were evaluated. Sample FEH0726 did not react
to any HIV-1 proteins; however, sample FEH0924
showed a strong reactivity to gp120 and weaker reactiv-
ity to p24, p31, p51 and p66 (data not shown).
All 32 samples showing reactivity to the HIV-2 gp36
peptide on the pepEIA were submitted to HIV-2 specific
PCR. Only three samples were positive by PCR: one dou-
ble- reactive on the pepEIA (FEH0089) and the two sam-
ples that reacted with the gp36 peptide only (FEH0726
and FEH0924). With the exception of these last two sam-
ples, all other 30 samples were also amplified using HIV-
1 specific primers and the majority of those analyzed
grouped with subtype C based on Stanford HIV Database
subtyping tool (Table 1). Interestingly, the three HIV-2
PCR positive samples were the only samples reactive to
both gp36 and gp105 on the INNO-LIA immunoblot. All
HIV-2 positive samples (FEH0089, FEH0726 and
FEH0924) pol gene (1507 bp fragment) were analyzed
and sequences clustered with HIV-2 subtype A (Table 1)
sequences after phylogenetic analysis.
In order to explore the cross-reactivity between HIV-1
and HIV-2 antibodies, a sub-group of HIV-1 positive
samples (n = 22), some displaying cross-reactivity to
HIV-2 (n = 16), were sequenced at the gp41 gene which
included the 14 amino acid present at the gp41 immu-
nodominant peptide used in the pepEIA. The gp41/36
IDR aa alignment showed that consensus sequence of 5
HIV-1 samples displaying no cross-reactivity to HIV-2
were not drastically different from 16 samples displaying
cross-reactivity to HIV-2 IDR peptide. Of note, we
found samples like FEH0871 and FEH0281 from both
groups showing some similar aa signatures in IDR pep-
tide to HIV-2 consensus such as A27 and R29 (Table 2).
Discussion
This study found a low prevalence (0.25%, CI 90% 0.01-
0.49) of HIV-2 in Maputo City, Southern Mozambique
among HIV positive population attending ARV clinics.
Additionally, of the three patients with HIV-2 infection,
one was co-infected with HIV-1 subtype C. The number
of dually infected individuals was lower than the HIV-2
infected subjects (one versus two). Barreto et al (1993)
described the presence of individuals infected with HIV-
2 in the city of Maputo since the late 80’s using serolo-
gical testing, and claimed that the entry of this virus was
due to post war movement of population growth espe-
cially among countries of Portuguese language in this
continent [22]. The overall prevalence of HIV-2 infected
individuals found in our study is very low when com-
pared to figures from West Africa where HIV-2 and
dual infections account for 1 to 10%. This is similar to
what is shown in West Africa where HIV-1 epidemic is
increasing and overtaking HIV-2 infections [3,23-26].
Figure 2 Evaluation of HIV-2 Western blot profile (New Lav
Blot II). The first two strips are negative (CTR Neg) and positive
(CTR Pos) controls. The other lanes show samples from patients
infected with HIV-2 (FEH 00726 and 0924), dually infected (FEH
0089) and dually reactive to HIV-1 and HIV-2 gp41/36 reactive,
except for sample FEH0871 which is reactive to gp41 peptide only.
The arrow indicates the molecular weights of viral proteins in kDa.
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as subtype A and due to a large (> 10%) genetic distance
between them it is likely that these patients represent
three different independent transmission events of HIV-
2 in country. The presence of subtype A isolates in
Mozambique fits with the hypothesis of introduction of
HIV-2 from West Africa, where this variant dominates
the epidemic. In fact, subtype A is the major HIV-2 var-
iant representing the epidemic in Portuguese Speaking
countries in West Africa such as Guine Bissau and Cape
Verde [27-30,12].
On the other hand, EIA using IDR peptides were able
to distinguish HIV-1 and HIV-2 infection with a sensi-
tivity of 100% and specificity of 97.6% (90% CI 99.7% to
99.9%). There was a high proportion of cross-reactivity
between HIV-1 and HIV-2 IDR peptides from sera of
individuals infected with HIV-1. It seems that sera of
HIV-2 mono-infected individuals solely recognize HIV-2
related IDR peptide in our pepEIA assay. The cross-
reactivity of some HIV-1 infected individuals can be a
source of false “dual infection” diagnosed in many publi-
cation based solely in IDR peptides EIA screening. In
this sense, our data are in agreement with Ciccaglione et
al [31]. This cross-reactivity can be minimized by 1:10
serum dilution in pepEIA which is an alternative strat-
egy to identify false-reactive HIV-2 samples. Our data
clearly demonstrated that the presence of gp105 and
gp36 bands in INNO-LIA assay was strongly associated
with HIV-2 infection. However, the same is not true
when solely one of these bands is recognized. In our
study the PCR reaction targeting HIV-2 pol region was
very sensitive and specific to identify truly HIV-2
infected individuals. This fact led us to conclude that
gp41/36 IDR pepEIA can be a good screening method
followed by INNO-LIA and PCR as confirmatory tests
for HIV-2 infection. This algorithm of test seems to be
very robust and enable us to identify 3 HIV-2 infections
among 1199 HIV positive sera.
The prevalence of HIV-2 in Mozambique and the
boundary countries need to be monitored throughout
the time to have a better understanding of its trend and
geographical distribution. Limited information exists
regarding commercial serological assays for HIV-2 diag-
nosis [32,33]. Therefore, the continuous survey for HIV-
2 need to be incorporated at serological and molecular
level in HIV surveillance programs in sub-Saharan coun-
tries. Guidelines for ART and algorithms for HIV diag-
nosis must take into account the prevalence of HIV-2
infection in a country. The new testing algorithm pro-
posed here can be implemented in regions where HIV-2
is reported to circulate in order to optimize the 1
st line
ARV regimens as well PMTCT interventions.
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